Alemtuzumab and Rituximab in Aplastic Anemia

• Status: Withdrawn
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitario Dr. Jose E. Gonzalez
• Treatments: Alemtuzumab; Rituximab

Criteria

Inclusion Criteria:

• Patients with aplastic anemia diagnosis

Exclusion Criteria:

• Patients with prior treatment with monoclonal antibodies and/or antithymocyte globulin.

• Patients with a diagnosis or history of HIV/AIDS, Hepatitis B, Hepatitis C, Cytomegalovirus.

• Patients who do not agree to sign a Letter of Informed Consent.